CLINICAL TRIAL: PHOSPHODIESTE RASE-5 INHIBITION IN DIASTOLIC HEART FAILURE (RELA

临床试验：磷酸二酯酶 5 抑制舒张性心力衰竭 (RELA

• 批准号: 8166988
• 负责人: MARTIN M LEWINTER
• 金额: $ 2.82万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166988
• 关键词: Chronic; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Diastolic heart failure; Double-Blind Method; EFRAC; Exercise; Funding; Grant; Heart failure; Institution; Measures; Patients; Performance; Placebos; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; improved; inhibitor/antagonist; placebo controlled study; sildenafil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a double-blind, placebo controlled study testing the hypothesis that chronic PDE-5 inhibition (sildenafil 80 mg tid for 24 weeks) improves exercise capacity and clinical status in patients with heart failure and normal ejection fraction. This study also measures the effect of this therapy on key pathophysiological parameters which are postulated to impact clinical status and exercise performance in diastolic heart failure. 120 patients will be studied. Approximately 10 here at FAHC. The primary endpoint is change in exercise capacity as assessed by peak VO2 after 24 weeks of double-blinded treatment PDE-5 inhibitor or placebo.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这是一项双盲、安慰剂对照研究，检验慢性PDE-5抑制（西地那非80 mg tid，持续24周）可改善心力衰竭和射血分数正常患者的运动能力和临床状态的假设。 本研究还测量了这种疗法对关键病理生理参数的影响，这些参数被认为会影响舒张性心力衰竭的临床状态和运动表现。 将对120名患者进行研究。 大约10个在FAHC。 主要终点是PDE-5抑制剂或安慰剂双盲治疗24周后通过峰值VO 2评估的运动能力变化。